Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes

We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-R...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical and aesthetic dermatology Vol. 18; no. 4; pp. 51 - 56
Main Authors Goldenberg, Gary, Schwartz, Ziv, Yousefian, Faraz
Format Journal Article
LanguageEnglish
Published United States Matrix Medical Communications 01.04.2025
Subjects
Online AccessGet full text
ISSN1941-2789
2689-9175

Cover

Loading…
Abstract We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm ). Five subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm ). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events. Investigator- and subject-graded GAIS scores showed a sharp increase to "much improved" at two weeks and increased to "very much improved" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study. The study included a small number of subjects (N=5). Our results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.
AbstractList We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm2).ObjectiveWe evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm2).Five subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm2). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events.MethodsFive subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm2). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events.Investigator- and subject-graded GAIS scores showed a sharp increase to "much improved" at two weeks and increased to "very much improved" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study.ResultsInvestigator- and subject-graded GAIS scores showed a sharp increase to "much improved" at two weeks and increased to "very much improved" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study.The study included a small number of subjects (N=5).LimitationsThe study included a small number of subjects (N=5).Our results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.ConclusionOur results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.
We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm ). Five subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm ). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events. Investigator- and subject-graded GAIS scores showed a sharp increase to "much improved" at two weeks and increased to "very much improved" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study. The study included a small number of subjects (N=5). Our results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.
Author Yousefian, Faraz
Schwartz, Ziv
Goldenberg, Gary
AuthorAffiliation 2 Dr. Schwartz is with Sidney Kimmel Medical College at Thomas Jefferson University, Department of Dermatology and Cutaneous Biology in Philadelphia, Pennsylvania
3 Dr. Yousefian is with the Philadelphia College of Osteopathic Medicine, Department of Dermatology and Mohs Surgery in Roswell, Georgia
1 Dr. Goldenberg is with the Icahn School of Medicine at Mount Sinai Hospital, Department of Dermatology in New York, New York
AuthorAffiliation_xml – name: 1 Dr. Goldenberg is with the Icahn School of Medicine at Mount Sinai Hospital, Department of Dermatology in New York, New York
– name: 3 Dr. Yousefian is with the Philadelphia College of Osteopathic Medicine, Department of Dermatology and Mohs Surgery in Roswell, Georgia
– name: 2 Dr. Schwartz is with Sidney Kimmel Medical College at Thomas Jefferson University, Department of Dermatology and Cutaneous Biology in Philadelphia, Pennsylvania
Author_xml – sequence: 1
  givenname: Gary
  surname: Goldenberg
  fullname: Goldenberg, Gary
  organization: Dr. Goldenberg is with the Icahn School of Medicine at Mount Sinai Hospital, Department of Dermatology in New York, New York
– sequence: 2
  givenname: Ziv
  surname: Schwartz
  fullname: Schwartz, Ziv
  organization: Dr. Schwartz is with Sidney Kimmel Medical College at Thomas Jefferson University, Department of Dermatology and Cutaneous Biology in Philadelphia, Pennsylvania
– sequence: 3
  givenname: Faraz
  surname: Yousefian
  fullname: Yousefian, Faraz
  organization: Dr. Yousefian is with the Philadelphia College of Osteopathic Medicine, Department of Dermatology and Mohs Surgery in Roswell, Georgia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40256344$$D View this record in MEDLINE/PubMed
BookMark eNpVkdtu1DAQhiPUim5LXwH5BqlcRPIhjmNuULTqQsWiVmi5jhx7sjFy7CV2Wu0L8ZyYUlA7N6M5_d8vzXlx4oOHV8WK1o0sJRH8pFgRWZGSikaeFZcx_sA5WCO5qF4XZxWmvGZVtSp-fQNTbu1-TOhuDCmYo1eT1Wg3wqwOR_Rg04gIfofayfrg4H5x1ud5q61BV-22fY82wbnwYP0efbV6zkbAuD-V9SiNgHYzqDSBTygMaKO0VS5fp0eVLxmSQrTxA1qHOEHKPeUNWj9C8uLtknSYIL4pTgflIlw-5Yvi--Z6t_5cbm8_3azbbXkghOJSDUC4HIzmogchesMHyijuMVMS9GAEpZXhhBhVQd0L3siBaMmwkURC0w_sovj4V_ew9BMYnW3PynWH2U5qPnZB2e7lxNux24f7LtOxqGucFa6eFObwc4GYuslGDc4pD2GJHSOSMl5XuM6rb5_D_lP-fYf9Bt__kfk
ContentType Journal Article
Copyright Copyright © 2025. Matrix Medical Communications. All rights reserved.
Copyright © 2025. Matrix Medical Communications. All rights reserved. 2025
Copyright_xml – notice: Copyright © 2025. Matrix Medical Communications. All rights reserved.
– notice: Copyright © 2025. Matrix Medical Communications. All rights reserved. 2025
DBID NPM
7X8
5PM
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2689-9175
EndPage 56
ExternalDocumentID PMC12007660
40256344
Genre Journal Article
GroupedDBID ---
53G
AAKDD
AAWTL
ABDBF
ACUHS
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
E3Z
EBD
EBS
EJD
ESX
F5P
HYE
NPM
OK1
RPM
TUS
7X8
5PM
ID FETCH-LOGICAL-p1120-afe159fdc57be77bd5f2320b03a9ecfd7224d511da4e6b7589f1c930d919e8bf3
ISSN 1941-2789
IngestDate Thu Aug 21 18:27:45 EDT 2025
Mon Apr 21 19:00:50 EDT 2025
Wed Apr 23 01:40:02 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Red-light
photodynamic therapy
safety
tolerability
aminolevulinic acid
cosmetic
actinic keratosis
Language English
License Copyright © 2025. Matrix Medical Communications. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p1120-afe159fdc57be77bd5f2320b03a9ecfd7224d511da4e6b7589f1c930d919e8bf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
FUNDING: Funding was provided by Biofrontera Inc.
DISCLOSURES: The authors declare no conflicts of interest relevant to the content of this article.
PMID 40256344
PQID 3192356406
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_12007660
proquest_miscellaneous_3192356406
pubmed_primary_40256344
PublicationCentury 2000
PublicationDate 2025-Apr
20250401
PublicationDateYYYYMMDD 2025-04-01
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-Apr
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical and aesthetic dermatology
PublicationTitleAlternate J Clin Aesthet Dermatol
PublicationYear 2025
Publisher Matrix Medical Communications
Publisher_xml – name: Matrix Medical Communications
SSID ssj0000389574
Score 2.3382082
Snippet We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10%...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 51
SubjectTerms Original Research
Title Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes
URI https://www.ncbi.nlm.nih.gov/pubmed/40256344
https://www.proquest.com/docview/3192356406
https://pubmed.ncbi.nlm.nih.gov/PMC12007660
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVrH8Zexr7XfaHCBhvBw45kO96bCU3LlrRjSyDsxciWRDxSuzROC_1B-527V_4ueej2YoKTyInuQffo-NxrQt4rTEvS5ZY3GimL68CzBHMSiw19F7LXELIeViPPTr2TBf-6dJetmGOqS4r4c3Kzs67kf6IK5yCuWCX7D5FtBoUT8BriC0eIMBzvFOMfSlpT3F0Pvq_yIpfl0-XRRYGdAkqN1bE_DN1BeJ5m-VpdbU0h5CBMUiMehNMQZYEJgCG_RtFghv68DDLauqp1QV46b8zowCwnwojsIayTONI3bMqcb1LjrBvnm3NVd4Ad1zWXZ9sC_nzlVfzdorPDhZv6TNM6FhLVygwjMW0UPeH_OF_L1pR2LFoX889kdQ1zZATxX-lVZznbKJ2WOu9EXIqbrtAxdDv-mHJtDrhjYeHu7sW7VSbMSly1se012D49iyaL6TSaHy3ne2SPObwj75jUDfTN9UsnQnWxXTuP2wbaDiOZPyIPq-mjYYmLx-Seyp6Q-7PKLPGU_GngQbvwoBU8KMKDAjxoHxwUwUE_AjQ-0QYYtAcMmmYUQkQbYNBc0xIYtAIGbYDxhdawoBBdWsOC1rB4RhaTo_n4xKoey2FdADm3LaEVcGAtE9ePle_H0tVAy-3YZiJQiZY-sEIJPF4KrrwY9qOBdpKA2TJwAjWKNXtO9jP4xS8JVTHjsfCAQmIySeRIMMYTn2tHKx-I4wE5rCc_gmUP72WJTAFuIoY7E9cDOnpAXpTBiC7K_iwRRx7POHx71AtT8wFsqd5_J0tXprW6g9K959mv7nDh1-RBC9M3ZL-43Kq3wFCL-J1B1V9rL55B
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Red-Light+Photodynamic+Therapy+with+10%25+Aminolevulinic+Acid+%28ALA%29+Following+Microneedling+in+the+Treatment+of+Facial+Actinic+Keratosis%3A+Cosmetic+and+Clinical+Outcomes&rft.jtitle=The+Journal+of+clinical+and+aesthetic+dermatology&rft.au=Goldenberg%2C+Gary&rft.au=Schwartz%2C+Ziv&rft.au=Yousefian%2C+Faraz&rft.date=2025-04-01&rft.issn=1941-2789&rft.volume=18&rft.issue=4&rft.spage=51&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-2789&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-2789&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-2789&client=summon